Boon Niels, Hul Gabby B J, Sicard Audrey, Kole Eveline, Van Den Berg Elisa R, Viguerie Nathalie, Langin Dominique, Saris Wim H M
Nutrition and Toxicology Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands.
Obesity (Silver Spring). 2006 Oct;14(10):1739-46. doi: 10.1038/oby.2006.200.
Evidence from a number of investigations indicates that calcium intake could be inversely related to body weight through alterations in the 1,25-OH(2)-D(3) metabolism. The objective of this study was to test whether energy and substrate metabolism and adipose tissue enzyme mRNA expression can be altered by changes in serum 1,25-OH(2)-D(3) through oral cholecalciferol supplementation in non-obese human subjects.
An intervention study was used with a treatment period of 7 days. During this intervention, energy expenditure (EE) and substrate metabolism were measured using indirect calorimetry at t = 0, 1, 3, and 7 days, and blood samples were obtained at t = -1, 0, 1, 2, 3, 5 and 7 days. Fat biopsies were obtained at t = 0 and 7 days for determination of expression of genes involved in lipolytic and lipogenic pathways. Subjects from the general community were studied in an ambulatory setting at a university hospital. Ten healthy young men (age, 28 +/- 3 years; BMI, 25.5 +/- 0.5 kg/m(2)) were recruited by local announcement, and all completed the study. All subjects received 2000 IU cholecalciferol/d for 7 days, and they were instructed to consume a low-cholecalciferol, low-calcium diet. EE, fat oxidation, and adipose tissue enzyme mRNA were the main outcome measures.
Despite a significant increase in serum 1,25-OH(2)-D(3) concentration at t = 5 and 7 days, no significant differences in substrate and energy metabolism nor mRNA concentrations of different lipid metabolism-related proteins were observed.
Seven-day supplementation with 2000 IU cholecalciferol/d together with a decrease in dietary calcium intake does not affect EE or substrate metabolism nor gene expression of proteins related to fat metabolism, despite a significant increase in serum 1,25-OH(2)-D(3) concentration.
多项调查证据表明，钙摄入量可能通过1,25 - 二羟维生素D₃代谢的改变与体重呈负相关。本研究的目的是测试在非肥胖人类受试者中，通过口服胆钙化醇补充剂改变血清1,25 - 二羟维生素D₃水平是否会改变能量和底物代谢以及脂肪组织酶mRNA表达。
采用干预研究，治疗期为7天。在此干预期间，在第0、1、3和7天使用间接测热法测量能量消耗（EE）和底物代谢，并在第 - 1、0、1、2、3、5和7天采集血样。在第0和7天获取脂肪活检样本，以测定参与脂解和脂肪生成途径的基因表达。在大学医院的门诊环境中对来自普通社区的受试者进行研究。通过当地公告招募了10名健康年轻男性（年龄，28±3岁；BMI，25.5±0.5kg/m²），所有受试者均完成了研究。所有受试者连续7天每天服用2000IU胆钙化醇，并被要求食用低胆钙化醇、低钙饮食。EE、脂肪氧化和脂肪组织酶mRNA是主要观察指标。
尽管在第5和7天血清1,25 - 二羟维生素D₃浓度显著升高，但未观察到底物和能量代谢以及不同脂质代谢相关蛋白的mRNA浓度有显著差异。
尽管血清1,25 - 二羟维生素D₃浓度显著升高，但连续7天每天补充2000IU胆钙化醇并减少膳食钙摄入量对EE或底物代谢以及与脂肪代谢相关的蛋白质基因表达没有影响。
